Nigeria, alongside seven other African nations, has joined an African-led initiative for HIV vaccine research and development.
Funded by the U.S. Agency for International Development (USAID) and led by the BRILLIANT consortium, the “HIV Vaccine Innovation, Science, and Technology Acceleration in Africa” (HIV-VISTA) project aims to develop a vaccine tailored to African populations. Other participating countries include South Africa, Zambia, Zimbabwe, Tanzania, Uganda, Kenya, and Mozambique.
Announcing the initiative in Abuja, Temitope Ilori, Director-General of Nigeria’s National Agency for the Control of AIDS (NACA), emphasized the importance of an effective HIV vaccine as HIV remains a significant public health challenge. She noted that, despite advances in infection reduction and virus control, a vaccine would provide a crucial tool in the battle against the epidemic.
The HIV-VISTA project has received over $45 million from USAID, with research and testing focused in Sub-Saharan Africa, where HIV rates remain highest globally. Alash’le Abimiku, Executive Director of the International Research Centre of Excellence (IRCE), underscored the consortium’s goal to leverage African innovation and science to address a health crisis that severely impacts the continent.
IHVN CEO, Patrick Dakum, and USAID’s Deputy Director of HIV/TB, Ezekiel James, highlighted the project’s potential to advance HIV epidemic control, bringing Africa closer to an effective HIV vaccine.
